[
  {
    "ts": null,
    "headline": "Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q2 2025 Update",
    "summary": "William von Muefflingâs Cantillon Capital grew to $17.34B by smartly balancing high-conviction stocks, trimming gains, and maintaining focus. See more here.",
    "url": "https://finnhub.io/api/news?id=cb616f1ef6b600f8834bcf920e96d1634dc4495a23724ab92e69fd07bf96abaf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754434423,
      "headline": "Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q2 2025 Update",
      "id": 136230428,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "William von Muefflingâs Cantillon Capital grew to $17.34B by smartly balancing high-conviction stocks, trimming gains, and maintaining focus. See more here.",
      "url": "https://finnhub.io/api/news?id=cb616f1ef6b600f8834bcf920e96d1634dc4495a23724ab92e69fd07bf96abaf"
    }
  },
  {
    "ts": null,
    "headline": "Alight Reports Second Quarter 2025 Results",
    "summary": "CHICAGO, August 05, 2025--Alight, Inc. (NYSE: ALIT), a leading cloud-based human capital and technology-enabled services provider, today reported results for the second quarter ended June 30, 2025.",
    "url": "https://finnhub.io/api/news?id=d9d8c1ac596194b1a5d87f7de51ab8661f22f7be6aed853fffb6037d94859d26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754393400,
      "headline": "Alight Reports Second Quarter 2025 Results",
      "id": 136212370,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "CHICAGO, August 05, 2025--Alight, Inc. (NYSE: ALIT), a leading cloud-based human capital and technology-enabled services provider, today reported results for the second quarter ended June 30, 2025.",
      "url": "https://finnhub.io/api/news?id=d9d8c1ac596194b1a5d87f7de51ab8661f22f7be6aed853fffb6037d94859d26"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Announces Appointment of David Simmons to the Company's Board of Directors",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that David Simmons has been appointed as the newest member of Viatris' Board of Directors.",
    "url": "https://finnhub.io/api/news?id=cdba5b6fa5898838b6f6a674eccbeb3da0e7c86fd7947e9e777ab6bfdc162c7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754391300,
      "headline": "Viatris Announces Appointment of David Simmons to the Company's Board of Directors",
      "id": 136212371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that David Simmons has been appointed as the newest member of Viatris' Board of Directors.",
      "url": "https://finnhub.io/api/news?id=cdba5b6fa5898838b6f6a674eccbeb3da0e7c86fd7947e9e777ab6bfdc162c7a"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne: Coveted Life Sciences Asset On Sale Due To Academic Pressures",
    "summary": "Headwaters Capital sees deep value in Bio-Techne as academic cuts weigh on shares. Learn why this life sciences leader could rebound in 2027âread the thesis.",
    "url": "https://finnhub.io/api/news?id=c0f8643ff6a9b2b5a2471056042b67ba3b521f1def3d5eb2f936fdb1bee4ce1a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754390700,
      "headline": "Bio-Techne: Coveted Life Sciences Asset On Sale Due To Academic Pressures",
      "id": 136213726,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1168939901/image_1168939901.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Headwaters Capital sees deep value in Bio-Techne as academic cuts weigh on shares. Learn why this life sciences leader could rebound in 2027âread the thesis.",
      "url": "https://finnhub.io/api/news?id=c0f8643ff6a9b2b5a2471056042b67ba3b521f1def3d5eb2f936fdb1bee4ce1a"
    }
  },
  {
    "ts": null,
    "headline": "Residual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing",
    "summary": "The residual DNA testing market is set to grow from USD 0.28 billion in 2025 to USD 0.37 billion by 2030, with a 6.0% CAGR. Key factors driving this growth include increasing biologics and biosimilars approvals and stringent regulatory frameworks. PCR technology holds the largest market share due to its high precision. The pharmaceutical and biotechnology sector dominates the demand for testing services. North America leads the market, fueled by robust R&D investments. Major players include Ther",
    "url": "https://finnhub.io/api/news?id=cf0a6d278a3ac55ee3a74c208b97ce2f74109b32cbb564291bfcfd3e2d89c286",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754382900,
      "headline": "Residual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing",
      "id": 136212352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The residual DNA testing market is set to grow from USD 0.28 billion in 2025 to USD 0.37 billion by 2030, with a 6.0% CAGR. Key factors driving this growth include increasing biologics and biosimilars approvals and stringent regulatory frameworks. PCR technology holds the largest market share due to its high precision. The pharmaceutical and biotechnology sector dominates the demand for testing services. North America leads the market, fueled by robust R&D investments. Major players include Ther",
      "url": "https://finnhub.io/api/news?id=cf0a6d278a3ac55ee3a74c208b97ce2f74109b32cbb564291bfcfd3e2d89c286"
    }
  },
  {
    "ts": null,
    "headline": "Down Syndrome Market Research and Global Forecast Report 2025-2035 | Rising Prevalence, Precision Medicine Advances, R&D Investments, and Advocacy-Driven Awareness Bolster Advances",
    "summary": "Down syndrome, caused by an extra chromosome 21, impacts physical and intellectual development. Advances in non-invasive prenatal testing (NIPT) and genetic screening offer earlier diagnosis, while cognitive enhancement drugs and supportive technologies expand treatment possibilities. Key growth factors include rising prevalence, increased R&D, and global advocacy. Challenges include high therapy costs and healthcare disparities. North America leads the market with strong infrastructure, followe",
    "url": "https://finnhub.io/api/news?id=dd833e22bbdd8bbd3692b61581549bb3147440624c9c9d2f981d555e176123c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754381940,
      "headline": "Down Syndrome Market Research and Global Forecast Report 2025-2035 | Rising Prevalence, Precision Medicine Advances, R&D Investments, and Advocacy-Driven Awareness Bolster Advances",
      "id": 136212373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Down syndrome, caused by an extra chromosome 21, impacts physical and intellectual development. Advances in non-invasive prenatal testing (NIPT) and genetic screening offer earlier diagnosis, while cognitive enhancement drugs and supportive technologies expand treatment possibilities. Key growth factors include rising prevalence, increased R&D, and global advocacy. Challenges include high therapy costs and healthcare disparities. North America leads the market with strong infrastructure, followe",
      "url": "https://finnhub.io/api/news?id=dd833e22bbdd8bbd3692b61581549bb3147440624c9c9d2f981d555e176123c5"
    }
  }
]